Effects of a tyramine-enriched meal on blood pressure response in healthy male volunteers treated with selegiline transdermal system 6 mg/24 hour

CNS Spectrums

Volumn 12, Issue 1, 2007, Pages 25-34

  Blob, Lawrence F ^a,b   Sharoky, Melvin ^c   Campbell, Bryan J ^d   Kemper, Eva M ^c   Gilmor, Michelle ^d   VanDenBerg, Chad M ^e,f   Azzaro, Albert J ^a,c  

^a Somerset Pharmaceuticals   (United States)

^b CeNeRx BioPharma   (United States)

^c Somerset ^*  (United States)

^d BRISTOL MYERS SQUIBB   (United States)

^e Center for Clinical Research

^f MERCER UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MONOAMINE OXIDASE INHIBITOR; PLACEBO; SELEGILINE; TYRAMINE;

ABDOMINAL PAIN; ACCIDENTAL INJURY; ADULT; ARTICLE; BLOOD PRESSURE; CHEESE; CLINICAL TRIAL; DEMOGRAPHY; DIZZINESS; DRUG EFFECT; DRUG SAFETY; FOOD DRUG INTERACTION; HEART RATE; HUMAN; HUMAN EXPERIMENT; HYPERTENSIVE CRISIS; INFECTION; MAJOR DEPRESSION; MALE; NORMAL HUMAN; OPEN STUDY; PARKINSON DISEASE; PHASE 1 CLINICAL TRIAL; PRESSOR RESPONSE; PRIORITY JOURNAL; STATISTICAL ANALYSIS; TRANSDERMAL PATCH; VITAL SIGN; VOLUNTEER;

EID: 33846538499     PISSN: 10928529     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1092852900020496     Document Type: Article

References (43)

1. VanDenBerg CM, Blob LF, Kemper EM, Azzaro AJ. Tyramine pharmacokinetics and reduced bioavailability with food. J Clin Pharmacol. 2003;43:604-609.
2. Sen NP. Analysis and Significance of Tyramine in Foods. J Food Sci. 1969;34:22-26.
3. McCabe BJ. Dietary tyramine and other presser amines in MAOI regimens: a review. J Am Diet Assoc. 1986;86:1059-1064.
4. Gardner DM, Shulman KI, Walker SE, Tailor SA. The making of a user friendly MAOI diet. J Clin Psychiatry. 1996;57:99-104.
5. Da Prada M, Zurcher G, Wuthrich I, Haefely WE. On tyramine, food, beverages and the reversible MAO inhibitor moclobemide. J Neural Transm Suppl. 1988;26:31-56.
6. Horwitz D, Lovenberg W, Engelman K, Sjoerdsma A. Monoamine oxidase inhibitors, tyramine, and cheese. JAMA. 1964;188:1108-1110.
7. Blackwell B, Marley E, Price J, Taylor D. Hypertensive interactions between monoamine oxidase inhibitors and foodstuffs. Br J Psychiatry. 1967;113:349-365.
8. Folks DG. Monoamine oxidase inhibitors: reappraisal of dietary considerations. J Clin Psychopharmacol. 1983;3:249-252.
9. Brown C, Taniguchi G, Yip K. The monoamine oxidase inhibitor-tyramine interaction. J Clin Pharmacol. 1989;29:529-532.
10. Asatoor AM, Levi AJ, Milne MD. Tranylcypromine and cheese. Lancet. 1963;54:733-734.
11. Sandler M, Glover V, Ashford A, Esmail A. The inhibition of tyramine oxidation and the tyramine hypertensive response ("cheese effect") may be independent phenomena. J Neural Transm. 1980;48:241-247.
12. Ghose K. Tyramine pressor test: implications and limitations. Methods Find Exp Clin Pharmacol. 1984;6:455-464.
13. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42:1206-1252.
14. Bieck PR, Antonin KH. Oral tyramine pressor test and the safety of monoamine oxidase inhibitor drugs: comparison of brofaromine and tranylcypromine in healthy subjects. J Clin Psychopharmacol. 1988;8:237-245.
15. Berlin I, Zimmer R, Cournot A, Payan C, Pedarriosse AM, Puech AJ. Determination and comparison of the pressor effect of tyramine during long-term moclobemide and tranylcypromine treatment in healthy volunteers. Clin Pharmacol Ther. 1989;46:344-351.
16. Shulman KI, Walker SE, MacKenzie S, Knowles S. Dietary restriction, tyramine, and the use of monoamine oxidase inhibitors. J Clin Psychopharmacol. 1989;9:397-402.
17. Shulman KI, Walker SE. Refining the MAOI diet: tyramine content of pizzas and soy products. J Clin Psychiatry. 1999;60:191-193.
18. Youdim MB, Weinstock M. Therapeutic applications of selective and non-selective inhibitors of monoamine oxidase A and B that do not cause significant tyramine potentiation. Neurotoxicology. 2004;25:243-250.
19. Heinonen EH, Myllyla V. Safety of selegiline (deprenyl) in the treatment of Parkinson's disease. Drug Saf. 1998;19(1):11-22.
20. Chrisp P, Mammen GJ, Sorkin EM. Selegiline. A review of its pharmacology, symptomatic benefits and protective potential in Parkinson's disease. Drugs Aging. 1991;1:228-248.
21. Knoll J. Deprenyl (selegiline): the history of its development and pharmacological action. Acta Neurol Scand Suppl. 1983;95:57-80.
22. Elsworth JD, Glover V, Reynolds GP, et al. Deprenyl administration in man: a selective monoamine oxidase B inhibitor without the 'cheese effect.' Psychopharmacol (Berl) 1978;57:33-38.
23. McGrath PJ, Stewart JW, Harrison W, Wager S, Nunes EN, Quitkin FM. A placebo-controlled trial of L-deprenyl in atypical depression. Psychopharmacol Bull. 1989;25:63-67.
24. Mendlewicz J, Youdim MB. L-Deprenil, a selective monoamine oxidase type B inhibitor, in the treatment of depression: a double blind evaluation. Br J Psychiatry. 1983;142:508-511.
25. Mann JJ, Aarons SF, Wilner PJ, et al. A controlled study of the antidepressant efficacy and side effects of (-)-deprenyl: a selective monoamine oxidase inhibitor. Arch Gen Psychiatry. 1989;46:45-50.
26. Sunderland T, Cohen RM, Molchan S, et al. High-dose selegiline in treatment-resistant older depressive patients. Arch Gen Psychiatry. 1994;51:607-615.
27. Schulz R, Antonin KH, Hoffmann E, et al. Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline. Clin Pharmacol Ther. 1989;46:528-536.
28. Lipper S, Murphy DL, Slater S, Buchsbaum MS. Comparative behavioral effects of clorgyline and pargyline in man: a preliminary evaluation. Psychopharmacology (Berl). 1979;62:123-128.
29. Sunderland T, Mueller EA, Cohen RM, Jimerson DC, Pickar D, Murphy DL. Tyramine pressor sensitivity changes during deprenyl treatment. Psychopharmacology (Berl). 1985;86:432-437.
30. Bodkin JA, Amsterdam JD. Transdermal selegiline in major depression: a double-blind, placebo-controlled, parallel-group study in outpatients. Am J Psychiatry. 2002;159:1869-1875.
31. Amsterdam JD. A double-blind, placebo-controlled trial of the safety and efficacy of selegiline transdermal system without dietary restrictions in patients with major depressive disorder. J Clin Psychiatry. 2003;64:208-214.
32. Barrett JS, Hochadel TJ, Morales RJ, et al. Pharmacokinetics and Safety of a Selegiline Transdermal System Relative to Single-Dose Oral Administration in the Elderly. Am J Ther. 1996;3:688-698.
33. Rohatagi S, Barrett JS, DeWitt KE, Morales RJ. Integrated pharmacokinetic and metabolic modeling of selegiline and metabolites after transdermal administration. Biopharm Drug Dispos. 1997;18:567-584.
34. Wecker L, James S, Copeland N, Pacheco MA. Transdermal selegiline: targeted effects on monoamine oxidases in the brain. Biol Psychiatry. 2003;54:1099-1104.
35. Mawhinney M, Cole D, Azzaro AJ. Daily transdermal administration of selegiline to guinea-pigs preferentially inhibits monoamine oxidase activity in brain when compared with intestinal and hepatic tissues. J Pharm Pharmacol. 2003;55:27-34.
36. Azzaro AJ, VanDenBerg CM, Blob LR et al. Tyramine pressor sensitivity during treatment with the selegiline transdermal system 6 mg/24 h in healthy subjects. J Clin Pharmacol. 2006;46:933-944.
37. Handbook of Clinical Dietetics. 2nd ed. New Haven, CT: Yale Universitv Press; 1992.
38. Lader MH, Sakalis G, Tansella M. Interactions between sympathomimetic amines and a new monoamine oxidase inhibitor. Psychopharmacologia. 1970;18:118-123.
39. Pickering TG, Harshfield GA, Kleinert HO, Blank S, Laragh JH. Blood pressure during normal daily activities, sleep, and exercise. Comparison of values in normal and hypertensive subjects. JAMA. 1982;247:992-996.
40. Walker SE, Shulman KI, Tailor SA, Gardner D. Tyramine content of previously restricted foods in monoamine oxidase inhibitor diets. J Clin Psychopharmacol. 1996;16:383-388.
41. Reimann IW, Firkusny L, Antonin KH, Bieck PR. Intravenous amine pressor tests in healthy volunteers. Within- and between subject variances and sex differences. Eur J Clin Pharmacol. 1992;42:137-141.
42. Cantarini MV, Painter CJ, Gilmore EM, Bolger C, Watkins CL, Hughes AM. Effect of oral linezolid on the pressor response to intravenous tyramine. Br J Clin Pharmacol. 2004;58:470-475.
43. Blackwell B, Mabbitt LA. Tyramine in cheese related to hypertensive crises after monoamine-oxidase inhibition. Lancet. 1965;62:938-940.